Clinical trials
Open Label clinical trials
Below are recruiting open label clinical trials, each written for real people, not researchers. We’re tracking 367 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07262476RecruitingPhase 3
Extension study of MHB018A for thyroid eye disease
This study tests a longer-term use of MHB018A for people with thyroid eye disease who did not fully respond to treatment in a previous study. It aims to see if further treatment can help improve eye bulging and other symptoms.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07263451Recruiting
Testing a new treatment for small, early breast cancers
This study tests if a new treatment called IRE (irreversible electroporation) can safely treat small, early-stage breast cancers. It's for people with a single, small tumor that has not been treated yet.
Hangzhou, ZhejiangAges 18 years+ - NCT07270003Recruiting
Ivarmacitinib for palmoplantar pustulosis
This trial tests a new oral medication, ivarmacitinib, for adults with palmoplantar pustulosis (PPP) who haven't gotten better with standard treatments. It aims to see if the drug is safe and effective for reducing the painful pustules on the palms and soles.
Xi'an, ShaanxiAges 18 years+ - NCT07282028RecruitingPhase 2/Phase 3
Spectacle hearing aid study for adults with mild to moderate hearing loss
This study tests a new hearing aid built into glasses for people who have mild to moderate hearing trouble, especially in noisy places. It aims to see if the glasses help you hear better without needing a traditional hearing aid.
Tel AvivAges 18 years+ - NCT07284797RecruitingPhase 1
Safety study for autoimmune disease and healthy volunteers
This trial is testing an experimental drug for safety in people with certain autoimmune diseases—like myositis, scleroderma, or Sjögren's disease—as well as in healthy volunteers. It aims to find out if the drug is safe enough to study further.
MelbourneAges 18–75 - NCT07288008Recruiting
Brain stimulation for anxiety in veterans
This study tests a gentle, non-invasive brain stimulation technique called tACS to see if it can help reduce anxiety in veterans. You would receive daily sessions of this stimulation over the scalp for several weeks.
Birmingham, AlabamaAges 19–70 - NCT07333066RecruitingPhase 3
Adding chemotherapy when first treatment response is limited
This trial tests whether adding a chemotherapy drug (docetaxel) to your current treatment (apalutamide) can help control prostate cancer that has spread and hasn't responded as well as hoped to apalutamide alone.
BayonneAges 18 years+ - NCT07357610RecruitingPhase 1
Drug interaction study of SIM0270 in healthy adults
This trial tests how SIM0270 interacts with other drugs (itraconazole, rifampin, midazolam) in healthy Chinese adults. It helps doctors understand if SIM0270 is safe and how it works in the body.
Jinan, ShandongAges 18–55 - NCT07362017RecruitingPhase 3
Ponesimod for moderate to severe plaque psoriasis
This trial tests an investigational drug called ponesimod for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at improving skin symptoms.
Glendale, ArizonaAges 18–65 - NCT07376642RecruitingEarly Phase 1
Testing IMV101 for relapsed B-cell lymphoma
This study tests an experimental drug called IMV101 for people with certain types of B-cell non-Hodgkin lymphoma that have come back or not responded to other treatments. It aims to see if the drug is safe and if it can shrink tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06675864RecruitingPhase 1/Phase 2
YTB323 for non-active progressive MS
This trial tests a new treatment called YTB323, which is a type of personalized cell therapy (CAR-T) designed to target your immune system and slow down MS progression. It is for people with non-active progressive MS who have seen their disability worsen recently.
Darlinghurst, New South WalesAges 18–60 - NCT06813339RecruitingEarly Phase 1
Testing a new drug in healthy people and those with heart condition
This trial tests a new medicine called UDP-003 in two groups: healthy volunteers and people who had a heart event (acute coronary syndrome) at least a year ago. The goal is to see if the drug is safe and how the body handles it, which could lead to better treatments for heart disease.
Adelaide, South AustraliaAges 18–79 - NCT07616687RecruitingPhase 4
Testing guselkumab to improve Crohn's disease control
This study tests whether guselkumab, a newer biologic medication, can better control active Crohn's disease symptoms and inflammation. You'll receive the medication and be monitored closely to see how well it works for you.
AmiensAges 18 years+ - NCT07402525Recruiting
Radiation after surgery for early-stage tongue cancer with risk factors
This trial tests whether adding radiation therapy after surgery helps prevent the return of early-stage tongue cancer in patients who have certain risk factors, such as nerve invasion or poorly differentiated cells. It is for people whose cancer was limited to the front two-thirds of the tongue and was completely removed.
Bengbu, AnhuiAges 18–70 - NCT07414316RecruitingEarly Phase 1
GK01 cell therapy for advanced lung or esophageal cancer
This trial tests a new cell treatment called GK01 for people with advanced lung cancer or esophageal cancer that has not responded to standard treatments. The study aims to see if this therapy can help shrink tumors or slow the cancer's growth.
NanchangAges 18–75 - NCT07429578Recruiting
Brain stimulation for anxiety and insomnia
This study tests whether a gentle, non-invasive brain stimulation technique (tACS) can help people who have both generalized anxiety and long-term sleep problems. It aims to see if this treatment can reduce anxiety and improve sleep.
São Paulo, São PauloAges 18–65 - NCT07434713Recruiting
Testing early response to Eylea 8mg for wet AMD
This study looks at how quickly fluid in the retina clears after starting treatment with a higher dose of Eylea (aflibercept 8mg) for wet age-related macular degeneration (AMD). It aims to understand if early fluid changes can predict long-term outcomes.
BernAges 50 years+ - NCT07439887RecruitingPhase 1/Phase 2
Study of an injection for Stargardt disease
This trial tests a single injection of a new medicine, RTx-021, into the eye for people with Stargardt disease. The goal is to see if it is safe and to find the right dose.
Bakersfield, CaliforniaAges 16 years+ - NCT07459647RecruitingPhase 2
Long-term study of ML-007C-MA for schizophrenia
This trial tests a new drug, ML-007C-MA, for adults with schizophrenia who may benefit from ongoing treatment. It aims to see how safe and effective the drug is over a longer period.
Lemon Grove, CaliforniaAges 18–65 - NCT07469683RecruitingPhase 2
Combination therapy for advanced kidney cancer after first-line treatment
This trial tests a combination of two drugs (SLC-3010 and axitinib) versus axitinib alone for people with advanced clear cell kidney cancer that has progressed after initial treatment. It aims to see if the combination is safer and more effective.
SeoulAges 19 years+ - NCT07473635Recruiting
Botox injections for nerve pain in CRPS — an early safety study
This study tests whether a specially targeted injection of botulinum toxin (like Botox) around nerves can help reduce pain from CRPS. It aims to see if the treatment is safe and doable for people with long-lasting CRPS.
Glostrup, Region SjællandAges 18 years+ - NCT07493044RecruitingPhase 1
Study of Super CAR-T for advanced liver cancer (GPC3-positive)
This trial tests a new cell therapy called Super CAR-T for people with advanced liver cancer that has GPC3 protein. It aims to see if the treatment is safe and effective. You may be eligible if your cancer has not responded to or stopped working on at least two standard treatments.
Guangzhou, GaungdongAges 18–75 - NCT07499284Recruiting
Haplo-Cord Stem Cell Transplant for Aplastic Anemia
This trial tests a new way of using a mix of donor stem cells (from a half-matched family member and a cord blood unit) to treat aplastic anemia, a condition where the bone marrow stops making enough blood cells. The goal is to see if this transplant approach is safe and helps rebuild healthy blood cells.
Suzhou, JiangsuAges 14 years+ - NCT07525869Recruiting
Pegfilgrastim to prevent low white blood cells in triple-negative breast cancer
This study tests whether a medicine called pegfilgrastim can help prevent dangerously low white blood cell counts in women with triple-negative breast cancer receiving a specific chemotherapy combination. Low white blood cells increase infection risk, so this medicine may help patients stay safer during treatment.
Seoul, Seodaemun-guAges 19–70
Hear when a new Open Label trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for open label?
- Yes. Clin2 currently lists 367 recruiting open label studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a open label trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a open label trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.